Sex and the patient with cardiovascular risk factors: focus on sildenafil - PubMed (original) (raw)
Review
. 2000 Dec 18:109 Suppl 9A:13S-21S; discussion 29S-30S.
doi: 10.1016/s0002-9343(00)00656-2.
Affiliations
- PMID: 11137498
- DOI: 10.1016/s0002-9343(00)00656-2
Review
Sex and the patient with cardiovascular risk factors: focus on sildenafil
R A Kloner. Am J Med. 2000.
Abstract
Erectile dysfunction (ED) is common in men with cardiovascular disease. The introduction of sildenafil citrate, the first oral agent for the treatment of this disorder, has increased awareness about the risks of sexual activity in cardiac patients and raised concerns about the safety of sildenafil in patients being treated for coronary disease. Sildenafil is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Sildenafil acts along the same general pathway as nitric oxide donors to increase cGMP levels and enhance erections. Sildenafil is a modest vasodilator that causes small decreases in systemic arterial pressure and mild preload and afterload reductions. It does not cause major decreases in blood pressure when administered with one or more standard antihypertensive agents. Because PDE5 is also present in small amounts in the systemic vasculature, sildenafil can cause a synergistic and major decrease in pressure when combined with organic nitrates. Use of organic nitrates is the only contraindication to sildenafil use. Data on sildenafil in patients with recent (less than 6 months) myocardial infarction (MI), unstable angina, stroke, and recent life-threatening arrhythmias are not available, so the drug should be used with caution in patients with unstable cardiac conditions. Placebo-controlled and open-label phase 2/3 trials including men with ischemic heart disease did not show an increase in MI or serious cardiovascular events in patients treated with sildenafil versus placebo. None of the serious cardiovascular events reported in these trials were considered treatment related by the investigators. There is a small but finite increased risk of developing ischemia or infarction with sexual activity. Therefore, before prescribing sildenafil or any current or future treatment for ED to patients with known cardiac disease or multiple cardiovascular risk factors, physicians should discuss the potential cardiac risk of sexual activity and perform a complete medical assessment, including an exercise stress test if appropriate.
Similar articles
- [Sex, erectile dysfunction, and the heart: a growing problem].
Görge G, Flüchter S, Kirstein M, Kunz T. Görge G, et al. Herz. 2003 Jun;28(4):284-90. doi: 10.1007/s00059-003-2478-8. Herz. 2003. PMID: 12825143 Review. German. - Overall cardiovascular profile of sildenafil citrate.
Zusman RM, Morales A, Glasser DB, Osterloh IH. Zusman RM, et al. Am J Cardiol. 1999 Mar 4;83(5A):35C-44C. doi: 10.1016/s0002-9149(99)00046-6. Am J Cardiol. 1999. PMID: 10078541 Review. - Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.
Conti CR, Pepine CJ, Sweeney M. Conti CR, et al. Am J Cardiol. 1999 Mar 4;83(5A):29C-34C. doi: 10.1016/s0002-9149(99)00045-4. Am J Cardiol. 1999. PMID: 10078540 - Cardiovascular risk and sildenafil.
Kloner RA. Kloner RA. Am J Cardiol. 2000 Jul 20;86(2A):57F-61F. doi: 10.1016/s0002-9149(00)00895-x. Am J Cardiol. 2000. PMID: 10899281 Review. - Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Webb DJ, et al. Am J Cardiol. 1999 Mar 4;83(5A):21C-28C. doi: 10.1016/s0002-9149(99)00044-2. Am J Cardiol. 1999. PMID: 10078539 Clinical Trial.
Cited by
- ST-elevation Myocardial Infarction and Complete Heart Block in a Nitrate-free Patient using a New Emerging Substance called Rhino.
Deliwala S, Haykal T, Dhillon H, Shafi S, Bachuwa G. Deliwala S, et al. Cureus. 2020 Apr 9;12(4):e7601. doi: 10.7759/cureus.7601. Cureus. 2020. PMID: 32399335 Free PMC article. - Pharmacological characterization of the relaxant effect induced by adrenomedullin in rat cavernosal smooth muscle.
Leite LN, Gonzaga NA, Tirapelli DP, Tirapelli LF, Tirapelli CR. Leite LN, et al. Braz J Med Biol Res. 2014 Oct;47(10):876-85. doi: 10.1590/1414-431x20143911. Epub 2014 Aug 15. Braz J Med Biol Res. 2014. PMID: 25140812 Free PMC article. - Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.
Schwinn DA, Roehrborn CG. Schwinn DA, et al. Int J Urol. 2008 Mar;15(3):193-9. doi: 10.1111/j.1442-2042.2007.01956.x. Int J Urol. 2008. PMID: 18304211 Free PMC article. Review. - Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke.
Li L, Jiang Q, Zhang L, Ding G, Gang Zhang Z, Li Q, Ewing JR, Lu M, Panda S, Ledbetter KA, Whitton PA, Chopp M. Li L, et al. Brain Res. 2007 Feb 9;1132(1):185-92. doi: 10.1016/j.brainres.2006.10.098. Epub 2006 Dec 26. Brain Res. 2007. PMID: 17188664 Free PMC article. - Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil.
Dietz U, Tries HP, Merkle W, Jaursch-Hancke C, Lambertz H. Dietz U, et al. Cardiovasc Diabetol. 2003 Aug 4;2:8. doi: 10.1186/1475-2840-2-8. Cardiovasc Diabetol. 2003. PMID: 12952551 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical